

Rebecca King

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5808907/publications.pdf>

Version: 2024-02-01

134
papers

2,180
citations

201575

27
h-index

276775

41
g-index

134
all docs

134
docs citations

134
times ranked

2904
citing authors

#	ARTICLE	IF	CITATIONS
1	Chronic lymphocytic leukemia (CLL) with Reed-Sternberg-like cells vs Classic Hodgkin lymphoma transformation of CLL: does this distinction matter?. <i>Blood Cancer Journal</i> , 2022, 12, 18.	2.8	9
2	Aberrant expression of lymphoid enhancer-binding factor 1 in Hodgkin lymphoma. <i>Human Pathology</i> , 2022, 125, 2-10.	1.1	2
3	PET2 response associated with survival in newly diagnosed diffuse large B-cell lymphoma: results of two independent prospective cohorts. <i>Blood Cancer Journal</i> , 2022, 12, 78.	2.8	1
4	Novel t(1;8)(p31.3;q21.3) <i>NFIA</i> - <i>RUNX1T1</i> Translocation in an Infant Erythroblastic Sarcoma. <i>American Journal of Clinical Pathology</i> , 2021, 156, 129-138.	0.4	10
5	Targeting of inflammatory pathways with R2CHOP in high-risk DLBCL. <i>Leukemia</i> , 2021, 35, 522-533.	3.3	28
6	Salicylates enhance CRM1 inhibitor antitumor activity by induction of S-phase arrest and impairment of DNA-damage repair. <i>Blood</i> , 2021, 137, 513-523.	0.6	9
7	Partial response or better at six months is prognostic of superior progression-free survival in Waldenström macroglobulinaemia patients treated with ibrutinib. <i>British Journal of Haematology</i> , 2021, 192, 542-550.	1.2	8
8	Mastocytosis. <i>American Journal of Clinical Pathology</i> , 2021, 155, 239-266.	0.4	12
9	Amyloid arthropathy in smoldering myeloma: Do not take it lightly. <i>Leukemia Research Reports</i> , 2021, 15, 100242.	0.2	2
10	Erythroblastic sarcoma transformation from a chronic myeloid neoplasm with <i>FGFR1</i> rearrangement presenting as a pleural effusion: a case report. <i>Journal of Hematopathology</i> , 2021, 14, 157-162.	0.2	0
11	EBV-Positive Plasmacytomas Involving a Nasopharyngeal Angiofibroma in an Adolescent. <i>Pediatric and Developmental Pathology</i> , 2021, 24, 264-268.	0.5	2
12	Clinical manifestations of, diagnostic approach to, and treatment of neurolymphomatosis in the rituximab era. <i>Blood Advances</i> , 2021, 5, 1379-1387.	2.5	18
13	The significance of gradient expression of chromosome region maintenance protein 1 (<i>exportin1</i>) in large cell lymphoma. <i>Haematologica</i> , 2021, 106, 2261-2264.	1.7	0
14	IGVL gene region usage correlates with distinct clinical presentation in IgM vs non-IgM light chain amyloidosis. <i>Blood Advances</i> , 2021, 5, 2101-2105.	2.5	7
15	Addition of Lenalidomide to R-CHOP Improves Outcomes in Newly Diagnosed Diffuse Large B-Cell Lymphoma in a Randomized Phase II US Intergroup Study ECOG-ACRIN E1412. <i>Journal of Clinical Oncology</i> , 2021, 39, 1329-1338.	0.8	60
16	Clinical, molecular, and prognostic comparisons between CCUS and lower-risk MDS: a study of 187 molecularly annotated patients. <i>Blood Advances</i> , 2021, 5, 2272-2278.	2.5	19
17	Type of tissue biopsy and outcomes in diffuse large B-cell lymphoma (DLBCL).. <i>Journal of Clinical Oncology</i> , 2021, 39, e13569-e13569.	0.8	1
18	Assessment of fixed-duration therapies for treatment-naïve Waldenström macroglobulinemia. <i>American Journal of Hematology</i> , 2021, 96, 945-953.	2.0	12

#	ARTICLE	IF	CITATIONS
19	Increased complexity of t(11;14) rearrangements in plasma cell neoplasms compared with mantle cell lymphoma. <i>Genes Chromosomes and Cancer</i> , 2021, 60, 678-686.	1.5	2
20	Patterns of therapy initiation during the first decade for patients with follicular lymphoma who were observed at diagnosis in the rituximab era. <i>Blood Cancer Journal</i> , 2021, 11, 133.	2.8	4
21	Epstein Barr Virus "Negative Lymphoplasmacytic Proliferation Limited to the Renal Allograft: A Unique Presentation of a Rare Disease. <i>Kidney International Reports</i> , 2021, 6, 2223-2227.	0.4	0
22	Disease outcomes and biomarkers of progression in smouldering Waldenström macroglobulinaemia. <i>British Journal of Haematology</i> , 2021, 195, 210-216.	1.2	12
23	Clinicopathologic Characteristics, Treatment, and Outcomes of Post-transplant Lymphoproliferative Disorders: A Single-institution Experience Using 2017 WHO Diagnostic Criteria. <i>HemaSphere</i> , 2021, 5, e640.	1.2	7
24	Lenalidomide in combination with R-CHOP produces high response rates and progression-free survival in new, untreated diffuse large B-cell lymphoma transformed from follicular lymphoma: results from the Phase 2 MC078E study. <i>Blood Cancer Journal</i> , 2021, 11, 160.	2.8	3
25	p53 immunohistochemistry discriminates between pure erythroid leukemia and reactive erythroid hyperplasia. <i>Journal of Hematopathology</i> , 2021, 14, 15-22.	0.2	6
26	Myeloid/Lymphoid Neoplasms Associated With Eosinophilia and Rearrangements of <i>PDGFRA</i> , <i>PDGFRB</i> , or <i>FGFR1</i> or With <i>PCM1-JAK2</i> . <i>American Journal of Clinical Pathology</i> , 2021, 155, 160-178.	0.4	42
27	Reactive Eosinophil Proliferations in Tissue and the Lymphocytic Variant of Hypereosinophilic Syndrome. <i>American Journal of Clinical Pathology</i> , 2021, 155, 211-238.	0.4	12
28	Eosinophilia/Hypereosinophilia in the Setting of Reactive and Idiopathic Causes, Well-Defined Myeloid or Lymphoid Leukemias, or Germline Disorders. <i>American Journal of Clinical Pathology</i> , 2021, 155, 179-210.	0.4	13
29	Addressing the Challenges of Eosinophilia and Mastocytosis. <i>American Journal of Clinical Pathology</i> , 2021, 155, 156-159.	0.4	0
30	MYC break-apart FISH probe set reveals frequent unbalanced patterns of uncertain significance when evaluating aggressive B-cell lymphoma. <i>Blood Cancer Journal</i> , 2021, 11, 184.	2.8	6
31	Follicular Lymphoma Tumor-Cell Transcriptional Programs Associate with Distinct Somatic Alterations and Tumor-Immune Microenvironments. <i>Blood</i> , 2021, 138, 1327-1327.	0.6	0
32	Parsaclisib in Combination with R-CHOP for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: Preliminary Results of a Phase 1/1b Study. <i>Blood</i> , 2021, 138, 1415-1415.	0.6	1
33	Mismatch-Repair Deficiency in Follicular Lymphoma Tumors Is Common and Associated with a Favorable Overall Survival. <i>Blood</i> , 2021, 138, 3523-3523.	0.6	0
34	PET2 Response Associated with Survival in Newly Diagnosed Diffuse Large B-Cell Lymphoma: Results of Two Independent Prospective Cohorts. <i>Blood</i> , 2021, 138, 2508-2508.	0.6	0
35	Ibrutinib monotherapy outside of clinical trial setting in Waldenström macroglobulinaemia: practice patterns, toxicities and outcomes. <i>British Journal of Haematology</i> , 2020, 188, 394-403.	1.2	41
36	Lymphomas arising in immune-privileged sites: insights into biology, diagnosis, and pathogenesis. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020, 476, 647-665.	1.4	55

#	ARTICLE	IF	CITATIONS
37	Impact of MYD88 ^{L265P} mutation status on histological transformation of Waldenström Macroglobulinemia. American Journal of Hematology, 2020, 95, 274-281.	2.0	33
38	The broad and challenging landscape of extranodal lymphoproliferations. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 476, 633-646.	1.4	2
39	IgM AL amyloidosis: delineating disease biology and outcomes with clinical, genomic and bone marrow morphological features. Leukemia, 2020, 34, 1373-1382.	3.3	40
40	The clinico-pathological spectrum of primary cutaneous lymphoma other than mycosis fungoides/Sezary syndrome. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 476, 683-699.	1.4	9
41	Update on lymphoproliferative disorders of the gastrointestinal tract: disease spectrum from indolent lymphoproliferations to aggressive lymphomas. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 476, 667-681.	1.4	33
42	Human Cancers Express TRAILshort, a Dominant Negative TRAIL Splice Variant, Which Impairs Immune Effector Cell Killing of Tumor Cells. Clinical Cancer Research, 2020, 26, 5759-5771.	3.2	5
43	Somatic copy number gains in MYC, BCL2, and BCL6 identifies a subset of aggressive alternative-DH/TH DLBCL patients. Blood Cancer Journal, 2020, 10, 117.	2.8	18
44	Analysis and impact of a multidisciplinary lymphoma virtual tumor board. Leukemia and Lymphoma, 2020, 61, 3351-3359.	0.6	14
45	Response to erythropoiesis-stimulating agents in patients with WHO-defined myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T). British Journal of Haematology, 2020, 189, e104-e108.	1.2	8
46	High level MYC amplification in B-cell lymphomas: is it a marker of aggressive disease?. Blood Cancer Journal, 2020, 10, 5.	2.8	22
47	Estimates and Timing of Therapy Initiation during the First Decade for Patients with Follicular Lymphoma Who Were Observed at Diagnosis. Blood, 2020, 136, 7-8.	0.6	2
48	Characteristics and outcome of patients with MYD88 wild-type Waldenström Macroglobulinemia.. Journal of Clinical Oncology, 2020, 38, 8550-8550.	0.8	3
49	Global Transcriptional States of Follicular Lymphoma B Cells Highlight Distinct Groups of Tumor Identity Associated with Somatic Alterations and Tumor Microenvironment. Blood, 2020, 136, 21-22.	0.6	0
50	Salicylates Potentiate and Broaden CRM1 Inhibitor Anti-Tumor Activity Via S-Phase Arrest and Impaired DNA-Damage Repair. Blood, 2020, 136, 17-18.	0.6	0
51	Spectrum of Hematological Malignancies in 130 Patients with Germline Predisposition Syndromes - Mayo Clinic Germline Predisposition Study. Blood, 2020, 136, 34-35.	0.6	0
52	The Expression of Chromosome Region Maintenance Protein 1 (CRM1) in Large Cell Lymphoma. Blood, 2020, 136, 39-40.	0.6	0
53	Lenalidomide/RCHOP (R2CHOP) Produces High Response Rates and Overall Survival in New, Untreated Diffuse Large B Cell Lymphoma Transformed from Follicular Lymphoma- Results from MC078E. Blood, 2020, 136, 47-48.	0.6	0
54	Clinical, Molecular, and Prognostic Comparisons between Clonal Cytopenias of Undetermined Significance and Lower-Risk Myelodysplastic Syndromes - a Study of 184 Molecularly Annotated Patients. Blood, 2020, 136, 35-36.	0.6	0

#	ARTICLE	IF	CITATIONS
55	Waldenström Macroglobulinemia in the Very Elderly (≥75 years): Clinical Characteristics and Outcomes. <i>Blood</i> , 2020, 136, 44-45.	0.6	8
56	Impact of concurrent indolent lymphoma on the clinical outcome of newly diagnosed diffuse large B-cell lymphoma. <i>Blood</i> , 2019, 134, 1289-1297.	0.6	26
57	Molecular Genetics in the Diagnosis and Biology of Lymphoid Neoplasms. <i>American Journal of Clinical Pathology</i> , 2019, 152, 277-301.	0.4	6
58	Late Relapses in Patients With Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy. <i>Journal of Clinical Oncology</i> , 2019, 37, 1819-1827.	0.8	44
59	Biology and prognostic impact of clonal plasmacytoid dendritic cells in chronic myelomonocytic leukemia. <i>Leukemia</i> , 2019, 33, 2466-2480.	3.3	66
60	The effect of CRM1 inhibition on human non-Hodgkin lymphoma cells. <i>Blood Cancer Journal</i> , 2019, 9, 24.	2.8	7
61	Application of a 5 Marker Panel to the Routine Diagnosis of Peripheral T-Cell Lymphoma With T-Follicular Helper Phenotype. <i>American Journal of Surgical Pathology</i> , 2019, 43, 1282-1290.	2.1	41
62	Novel germline missense <i>DDX41</i> variant in a patient with an adult-onset myeloid neoplasm with excess blasts without dysplasia. <i>Leukemia and Lymphoma</i> , 2019, 60, 1337-1339.	0.6	9
63	False-negative rates for <i>MYC</i> fluorescence <i>in situ</i> hybridization probes in B-cell neoplasms. <i>Haematologica</i> , 2019, 104, e248-e251.	1.7	43
64	Role of systemic high-dose methotrexate and combined approaches in the management of vitreoretinal lymphoma: A single center experience 1990-2018. <i>American Journal of Hematology</i> , 2019, 94, 291-298.	2.0	40
65	Potential Factors That Impact Lenalidomide/R-CHOP Efficacy in Previously Untreated Diffuse Large B-Cell Lymphoma in the ROBUST and ECOG-ACRIN 1412 Studies. <i>Blood</i> , 2019, 134, 4092-4092.	0.6	4
66	Clinical Features and Treatment for Neurolymphomatosis in the Rituximab Era: Single Institution Experience. <i>Blood</i> , 2019, 134, 4129-4129.	0.6	1
67	Response to Erythropoiesis Stimulating Agents in Patients with WHO-Defined Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T). <i>Blood</i> , 2019, 134, 4182-4182.	0.6	1
68	Waldenström Macroglobulinemia with Excess Plasma Cells: Is It a Distinct Entity?. <i>Blood</i> , 2019, 134, 1532-1532.	0.6	0
69	Event-Free Survival at 24 Months Following Autologous Stem Cell Transplant in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2019, 134, 2896-2896.	0.6	2
70	Genomic Landscape Including Novel Mutational Drivers in Relapsed/Refractory Diffuse Large B Cell Lymphoma. <i>Blood</i> , 2019, 134, 919-919.	0.6	0
71	Clustering of Transcriptomic Signatures in Newly Diagnosed Diffuse Large B-Cell Lymphoma Identifies Two High-Risk Subgroups Which Increase in Prevalence at Relapse. <i>Blood</i> , 2019, 134, 923-923.	0.6	0
72	Immunoglobulin Variable Gene Region (IGVL) Usage Correlates with Distinct Clinical Presentation in IgM Versus Non-IgM Light Chain Amyloidosis. <i>Blood</i> , 2019, 134, 1770-1770.	0.6	0

#	ARTICLE	IF	CITATIONS
73	Genomic Analysis of R2CHOP-Treated DLBCL Reveals a High-Risk Population Driven By Inflammatory Pathways. <i>Blood</i> , 2019, 134, 1480-1480.	0.6	0
74	High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology. <i>Blood</i> , 2018, 131, 2060-2064.	0.6	167
75	Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia. <i>Annals of Hematology</i> , 2018, 97, 1417-1425.	0.8	71
76	Reply to Castillo et al.. <i>American Journal of Hematology</i> , 2018, 93, E71-E73.	2.0	3
77	Rapid, real time pathology review for ECOG/ACRIN 1412: a novel and successful paradigm for future lymphoma clinical trials in the precision medicine era. <i>Blood Cancer Journal</i> , 2018, 8, 27.	2.8	10
78	MYD88 mutation status does not impact overall survival in Waldenström macroglobulinemia. <i>American Journal of Hematology</i> , 2018, 93, 187-194.	2.0	57
79	Lenalidomide plus R-CHOP21 in newly diagnosed diffuse large B-cell lymphoma (DLBCL): long-term follow-up results from a combined analysis from two phase 2 trials. <i>Blood Cancer Journal</i> , 2018, 8, 108.	2.8	32
80	Small B-Cell Lymphomas. , 2018, , 213-270.e3.		0
81	Defining Lymphoplasmacytic Lymphoma. <i>American Journal of Clinical Pathology</i> , 2018, 150, 168-176.	0.4	5
82	A Test Utilization Approach to the Diagnostic Workup of Isolated Eosinophilia in Otherwise Morphologically Unremarkable Bone Marrow. <i>American Journal of Clinical Pathology</i> , 2018, 150, 421-431.	0.4	12
83	Predictors of symptomatic hyperviscosity in Waldenström macroglobulinemia. <i>American Journal of Hematology</i> , 2018, 93, 1384-1393.	2.0	24
84	Bone Marrow Biopsy Operator Experience and Impact on Aspirate, Biopsy, and Ancillary Testing Quality. <i>Mayo Clinic Proceedings Innovations, Quality & Outcomes</i> , 2018, 2, 241-247.	1.2	5
85	Kidney Involvement of Patients with Waldenström Macroglobulinemia and Other IgM-Producing B Cell Lymphoproliferative Disorders. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018, 13, 1037-1046.	2.2	46
86	An Analysis of a Multidisciplinary Lymphoma Virtual Tumor Board with Regional and International Participation. <i>Blood</i> , 2018, 132, 2247-2247.	0.6	2
87	Clinical Characteristics and Outcomes of an Analysis of a Single Institution Experience of the 2017 World Health Organization (WHO) Classification of Post-Transplant Lymphoproliferative Disorders (PTLD). <i>Blood</i> , 2018, 132, 456-456.	0.6	4
88	IgM Associated Light Chain (AL) Amyloidosis: Delineating Disease Biology with Clinical, Genomic and Bone Marrow Morphological Features. <i>Blood</i> , 2018, 132, 4460-4460.	0.6	1
89	High Efficacy of Lenalidomide Plus R-CHOP (R2CHOP) Combination in First Line Treatment of Activated B-Cell (ABC) DLBCL Defined Using Gene-Expression Profiling: A Combined Analysis from Two Phase 2 Trials. <i>Blood</i> , 2018, 132, 2962-2962.	0.6	1
90	Long term follow-up (FU) of lenalidomide plus R-CHOP therapy in patients with newly diagnosed diffuse large b-cell lymphoma (DLBCL): Combined analysis from two phase 2 trials.. <i>Journal of Clinical Oncology</i> , 2018, 36, 7562-7562.	0.8	1

#	ARTICLE	IF	CITATIONS
91	High Level MYC Amplification in Aggressive B-Cell Lymphomas: Is It a Marker of Aggressive Disease?. Blood, 2018, 132, 1693-1693.	0.6	1
92	Ibrutinib Therapy in Patients with Waldenstrom Macroglobulinemia: Outcomes Outside of Clinical Trial Setting. Blood, 2018, 132, 1606-1606.	0.6	1
93	Role of Systemic High-Dose Methotrexate and Combined Approaches in the Management of Vitreoretinal Diffuse Large B-Cell Lymphoma: A Single Center Experience 1990-2018. Blood, 2018, 132, 574-574.	0.6	0
94	Indoleamine 2,3-Dioxygenase-1 Expressing Dendritic Cell Populations Are Associated with Tumor-Induced Immune Tolerance & Aggressive Disease Biology in Chronic Myelomonocytic Leukemia. Blood, 2018, 132, 4344-4344.	0.6	0
95	Impact of MYD88L265P mutation Status on Histological Transformation of Waldenstrom Macroglobulinemia. Blood, 2018, 132, 2884-2884.	0.6	1
96	Epstein-Barr Virus Status in Diffuse Large B Cell Lymphoma Post-Transplant Lymphoproliferative Disorder. Blood, 2018, 132, 2979-2979.	0.6	0
97	Mantle cell lymphoma with a novel t(11;12)(q13;p11.2): a proposed alternative mechanism of CCND1 up-regulation. Human Pathology, 2017, 64, 207-212.	1.1	6
98	Diagnosis and Management of Waldenström Macroglobulinemia. JAMA Oncology, 2017, 3, 1257.	3.4	110
99	Liver dysfunction in chronic lymphocytic leukemia: Prevalence, outcomes, and pathological findings. American Journal of Hematology, 2017, 92, 1362-1369.	2.0	13
100	Molecular Malleasance Mediating Myeloid Malignancies: The Genetics of Acute Myeloid Leukemia. Methods in Molecular Biology, 2017, 1633, 1-17.	0.4	3
101	Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment-naïve patients with Waldenstrom macroglobulinemia. British Journal of Haematology, 2017, 179, 98-105.	1.2	25
102	Effects of TTI-621 (SIRPαFc) on CD47 and serum cytokines associated with phagocytosis in subjects with relapsed, refractory hematologic malignancies: Pharmacodynamic findings from a first-in-human clinical trial.. Journal of Clinical Oncology, 2017, 35, 112-112.	0.8	3
103	Prognostic and therapeutic impact of cytogenetic abnormalities in patients with myelodysplastic/myeloproliferative neoplasms, unclassifiable.. Journal of Clinical Oncology, 2017, 35, 7058-7058.	0.8	0
104	Morphologic Features of ALK-negative Anaplastic Large Cell Lymphomas With DUSP22 Rearrangements. American Journal of Surgical Pathology, 2016, 40, 36-43.	2.1	103
105	Predictors of survival in refractory anemia with ring sideroblasts and thrombocytosis (RARS) and the role of next-generation sequencing. American Journal of Hematology, 2016, 91, 492-498.	2.0	70
106	Vascular events and risk factors for thrombosis in refractory anemia with ring sideroblasts and thrombocytosis. Leukemia, 2016, 30, 2273-2275.	3.3	23
107	First report of MYD88L265P somatic mutation in IgM-associated light-chain amyloidosis. Blood, 2016, 127, 2936-2938.	0.6	17
108	Broadening the Morphologic Spectrum of Bartonella henselae Lymphadenitis. American Journal of Surgical Pathology, 2016, 40, 342-347.	2.1	8

#	ARTICLE	IF	CITATIONS
109	Lymphoplasmacytic Lymphoma With a Non-IgM Paraprotein Shows Clinical and Pathologic Heterogeneity and May Harbor MYD88L265P Mutations. <i>American Journal of Clinical Pathology</i> , 2016, 145, 843-851.	0.4	43
110	Safety and Accuracy of Percutaneous Image-Guided Core Biopsy of the Spleen. <i>American Journal of Roentgenology</i> , 2016, 206, 655-659.	1.0	54
111	Bendamustine and Rituximab Versus Dexamethasone, Rituximab and Cyclophosphamide in Patients with Waldenstrom Macroglobulinemia (WM). <i>Blood</i> , 2016, 128, 2968-2968.	0.6	4
112	Dexamethasone, Rituximab and Cyclophosphamide (DRC) As Salvage Therapy for Waldenstrom Macroglobulinemia. <i>Blood</i> , 2016, 128, 2972-2972.	0.6	2
113	Lenalidomide Combined with R-CHOP (R2CHOP) Overcomes Negative Prognostic Impact of ABC Molecular Subtype in Newly Diagnosed Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2016, 128, 3035-3035.	0.6	5
114	Dexamethasone, rituximab and cyclophosphamide (DRC) in relapsed/refractory (R/R) and treatment naïve (TN) Waldenström macroglobulinemia (WM).. <i>Journal of Clinical Oncology</i> , 2016, 34, 7552-7552.	0.8	1
115	Clinical Presentation and Outcome of Patients with Myeloid Differentiation Factor 88 Gene (MYD88) Wild-Type Waldenstrom Macroglobulinemia. <i>Blood</i> , 2016, 128, 2960-2960.	0.6	15
116	Liver Biopsy in Patients with Chronic Lymphocytic Leukemia: Indications and Pathological Findings. <i>Blood</i> , 2016, 128, 5592-5592.	0.6	1
117	Lymphocytic variant of hypereosinophilic syndrome mimicking peripheral T-cell lymphoma in a young woman. <i>Blood</i> , 2016, 127, 268.	0.6	0
118	Atypical cutaneous β_1 T cell proliferation with morphologic features of lymphoma but with clinical features and course of PLEVA or lymphomatoid papulosis. <i>Journal of Cutaneous Pathology</i> , 2015, 42, 1012-1017.	0.7	15
119	Morphologically Occult Systemic Mastocytosis in Bone Marrow. <i>American Journal of Clinical Pathology</i> , 2015, 144, 493-502.	0.4	17
120	CLL/SLL diagnosed in an adolescent. <i>Pediatric Blood and Cancer</i> , 2014, 61, 1107-1110.	0.8	5
121	Use of flow cytometry in the diagnosis of lymphoproliferative disorders in fluid specimens. <i>Diagnostic Cytopathology</i> , 2014, 42, 664-670.	0.5	31
122	Hodgkin Lymphoma. <i>Advances in Anatomic Pathology</i> , 2014, 21, 12-25.	2.4	21
123	Genetics of Diffuse Large B-Cell Lymphoma. <i>Cancer Journal (Sudbury, Mass)</i> , 2014, 20, 43-47.	1.0	4
124	Near-haploid B lymphoblastic leukemia with an apparent hyperdiploid karyotype: the critical role of SNP analysis in establishing proper diagnosis. <i>Journal of Hematopathology</i> , 2014, 7, 27-32.	0.2	4
125	Acquired isochromosome 12p, somatic TP53 and PTEN mutations, and a germline ATM variant in an adolescent male with concurrent acute megakaryoblastic leukemia and mediastinal germ cell tumor. <i>Cancer Genetics</i> , 2014, 207, 153-159.	0.2	21
126	Iron-laden macrophage in autoimmune disease. <i>Blood</i> , 2014, 123, 469-469.	0.6	1

#	ARTICLE	IF	CITATIONS
127	IgM Multiple Myeloma. American Journal of Clinical Pathology, 2013, 140, 519-524.	0.4	19
128	A Comparative Analysis of Molecular Genetic and Conventional Cytogenetic Detection of Diagnostically Important Translocations in More Than 400 Cases of Acute Leukemia, Highlighting the Frequency of False-Negative Conventional Cytogenetics. American Journal of Clinical Pathology, 2011, 135, 921-928.	0.4	28
129	Interference with the Jaff� method for creatinine following 5-aminolevulinic acid administration. Photodiagnosis and Photodynamic Therapy, 2010, 7, 268-274.	1.3	7
130	Extracavitary primary effusion lymphoma in an HIV-positive patient with Kaposi sarcoma-associated. Community Oncology, 2009, 6, 523-525.	0.2	1
131	Routine Cerebrospinal Fluid Enterovirus Polymerase Chain Reaction Testing Reduces Hospitalization and Antibiotic Use for Infants 90 Days of Age or Younger. Pediatrics, 2007, 120, 489-496.	1.0	87
132	FACTORS INFLUENCING THE DECISION TO TEST YOUNG INFANTS FOR HERPES SIMPLEX VIRUS INFECTION. Pediatric Infectious Disease Journal, 2007, 26, 1156-1158.	1.1	18
133	Methionine Aminopeptidase 2 Inhibition Is an Effective Treatment Strategy for Neuroblastoma in Preclinical Models. Clinical Cancer Research, 2005, 11, 2680-2685.	3.2	33
134	Detection of Single-Copy Chromosome 17q Gain in Human Neuroblastomas Using Real-Time Quantitative Polymerase Chain Reaction. Modern Pathology, 2003, 16, 1248-1256.	2.9	27